Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 156

1.

ATP hydrolysis-coupled peptide translocation mechanism of Mycobacterium tuberculosis ClpB.

Yu H, Lupoli TJ, Kovach A, Meng X, Zhao G, Nathan CF, Li H.

Proc Natl Acad Sci U S A. 2018 Oct 9;115(41):E9560-E9569. doi: 10.1073/pnas.1810648115. Epub 2018 Sep 26.

2.

Antimalarial proteasome inhibitor reveals collateral sensitivity from intersubunit interactions and fitness cost of resistance.

Kirkman LA, Zhan W, Visone J, Dziedziech A, Singh PK, Fan H, Tong X, Bruzual I, Hara R, Kawasaki M, Imaeda T, Okamoto R, Sato K, Michino M, Alvaro EF, Guiang LF, Sanz L, Mota DJ, Govindasamy K, Wang R, Ling Y, Tumwebaze PK, Sukenick G, Shi L, Vendome J, Bhanot P, Rosenthal PJ, Aso K, Foley MA, Cooper RA, Kafsack B, Doggett JS, Nathan CF, Lin G.

Proc Natl Acad Sci U S A. 2018 Jul 17;115(29):E6863-E6870. doi: 10.1073/pnas.1806109115. Epub 2018 Jul 2.

3.

Identification of a Mycothiol-Dependent Nitroreductase from Mycobacterium tuberculosis.

Negri A, Javidnia P, Mu R, Zhang X, Vendome J, Gold B, Roberts J, Barman D, Ioerger T, Sacchettini JC, Jiang X, Burns-Huang K, Warrier T, Ling Y, Warren JD, Oren DA, Beuming T, Wang H, Wu J, Li H, Rhee KY, Nathan CF, Liu G, Somersan-Karakaya S.

ACS Infect Dis. 2018 May 11;4(5):771-787. doi: 10.1021/acsinfecdis.7b00111. Epub 2018 Feb 21.

4.

Evidence for dispensability of protein kinase R in host control of tuberculosis.

Mundhra S, Bryk R, Hawryluk N, Zhang T, Jiang X, Nathan CF.

Eur J Immunol. 2018 Apr;48(4):612-620. doi: 10.1002/eji.201747180. Epub 2018 Feb 28.

PMID:
29436711
5.

Structure of human immunoproteasome with a reversible and noncompetitive inhibitor that selectively inhibits activated lymphocytes.

Santos RLA, Bai L, Singh PK, Murakami N, Fan H, Zhan W, Zhu Y, Jiang X, Zhang K, Assker JP, Nathan CF, Li H, Azzi J, Lin G.

Nat Commun. 2017 Nov 22;8(1):1692. doi: 10.1038/s41467-017-01760-5.

6.

Introduction of Laurie H. Glimcher, MD.

Nathan CF.

J Clin Invest. 2017 Oct 2;127(10):3575. doi: 10.1172/JCI97404. Epub 2017 Oct 2. No abstract available.

7.

Distinct Spatiotemporal Dynamics of Peptidoglycan Synthesis between Mycobacterium smegmatis and Mycobacterium tuberculosis.

Botella H, Yang G, Ouerfelli O, Ehrt S, Nathan CF, Vaubourgeix J.

MBio. 2017 Sep 12;8(5). pii: e01183-17. doi: 10.1128/mBio.01183-17.

8.

Rifamycin action on RNA polymerase in antibiotic-tolerant Mycobacterium tuberculosis results in differentially detectable populations.

Saito K, Warrier T, Somersan-Karakaya S, Kaminski L, Mi J, Jiang X, Park S, Shigyo K, Gold B, Roberts J, Weber E, Jacobs WR Jr, Nathan CF.

Proc Natl Acad Sci U S A. 2017 Jun 13;114(24):E4832-E4840. doi: 10.1073/pnas.1705385114. Epub 2017 May 30.

9.

Rational Design of Selective and Bioactive Inhibitors of the Mycobacterium tuberculosis Proteasome.

Totaro KA, Barthelme D, Simpson PT, Jiang X, Lin G, Nathan CF, Sauer RT, Sello JK.

ACS Infect Dis. 2017 Feb 10;3(2):176-181. doi: 10.1021/acsinfecdis.6b00172. Epub 2016 Dec 5.

10.

Brief treatment with a highly selective immunoproteasome inhibitor promotes long-term cardiac allograft acceptance in mice.

Sula Karreci E, Fan H, Uehara M, Mihali AB, Singh PK, Kurdi AT, Solhjou Z, Riella LV, Ghobrial I, Laragione T, Routray S, Assaker JP, Wang R, Sukenick G, Shi L, Barrat FJ, Nathan CF, Lin G, Azzi J.

Proc Natl Acad Sci U S A. 2016 Dec 27;113(52):E8425-E8432. doi: 10.1073/pnas.1618548114. Epub 2016 Dec 12.

11.

Reconstitution of a Mycobacterium tuberculosis proteostasis network highlights essential cofactor interactions with chaperone DnaK.

Lupoli TJ, Fay A, Adura C, Glickman MS, Nathan CF.

Proc Natl Acad Sci U S A. 2016 Dec 6;113(49):E7947-E7956. Epub 2016 Nov 21.

12.

Immunoproteasome β5i-Selective Dipeptidomimetic Inhibitors.

Singh PK, Fan H, Jiang X, Shi L, Nathan CF, Lin G.

ChemMedChem. 2016 Oct 6;11(19):2127-2131. doi: 10.1002/cmdc.201600384. Epub 2016 Aug 25.

13.

N-methylation of a bactericidal compound as a resistance mechanism in Mycobacterium tuberculosis.

Warrier T, Kapilashrami K, Argyrou A, Ioerger TR, Little D, Murphy KC, Nandakumar M, Park S, Gold B, Mi J, Zhang T, Meiler E, Rees M, Somersan-Karakaya S, Porras-De Francisco E, Martinez-Hoyos M, Burns-Huang K, Roberts J, Ling Y, Rhee KY, Mendoza-Losana A, Luo M, Nathan CF.

Proc Natl Acad Sci U S A. 2016 Aug 2;113(31):E4523-30. doi: 10.1073/pnas.1606590113. Epub 2016 Jul 18.

14.

Human studies at JEM: Immunology and beyond.

Casanova JL, Nathan CF, Nussenzweig MC; Editors.

J Exp Med. 2016 Apr 4;213(4):467-8. doi: 10.1084/jem.20160211. Epub 2016 Mar 14. No abstract available.

15.

E1 of α-ketoglutarate dehydrogenase defends Mycobacterium tuberculosis against glutamate anaplerosis and nitroxidative stress.

Maksymiuk C, Balakrishnan A, Bryk R, Rhee KY, Nathan CF.

Proc Natl Acad Sci U S A. 2015 Oct 27;112(43):E5834-43. doi: 10.1073/pnas.1510932112. Epub 2015 Oct 1. Erratum in: Proc Natl Acad Sci U S A. 2015 Nov 10;112(45):E6257.

16.

Target-based screen against a periplasmic serine protease that regulates intrabacterial pH homeostasis in Mycobacterium tuberculosis.

Zhao N, Darby CM, Small J, Bachovchin DA, Jiang X, Burns-Huang KE, Botella H, Ehrt S, Boger DL, Anderson ED, Cravatt BF, Speers AE, Fernandez-Vega V, Hodder PS, Eberhart C, Rosen H, Spicer TP, Nathan CF.

ACS Chem Biol. 2015 Feb 20;10(2):364-71. doi: 10.1021/cb500746z. Epub 2014 Dec 5.

17.

Oxathiazolones Selectively Inhibit the Human Immunoproteasome over the Constitutive Proteasome.

Fan H, Angelo NG, Warren JD, Nathan CF, Lin G.

ACS Med Chem Lett. 2014 Feb 3;5(4):405-10. doi: 10.1021/ml400531d. eCollection 2014 Apr 10.

18.

Synthetic calanolides with bactericidal activity against replicating and nonreplicating Mycobacterium tuberculosis.

Zheng P, Somersan-Karakaya S, Lu S, Roberts J, Pingle M, Warrier T, Little D, Guo X, Brickner SJ, Nathan CF, Gold B, Liu G.

J Med Chem. 2014 May 8;57(9):3755-72. doi: 10.1021/jm4019228. Epub 2014 Apr 24.

PMID:
24694175
19.

Benzimidazole-based compounds kill Mycobacterium tuberculosis.

Gong Y, Somersan Karakaya S, Guo X, Zheng P, Gold B, Ma Y, Little D, Roberts J, Warrier T, Jiang X, Pingle M, Nathan CF, Liu G.

Eur J Med Chem. 2014 Mar 21;75:336-53. doi: 10.1016/j.ejmech.2014.01.039. Epub 2014 Jan 31.

PMID:
24556148
20.

Genetic regulation of vesiculogenesis and immunomodulation in Mycobacterium tuberculosis.

Rath P, Huang C, Wang T, Wang T, Li H, Prados-Rosales R, Elemento O, Casadevall A, Nathan CF.

Proc Natl Acad Sci U S A. 2013 Dec 3;110(49):E4790-7. doi: 10.1073/pnas.1320118110. Epub 2013 Nov 18.

21.

Nitrite produced by Mycobacterium tuberculosis in human macrophages in physiologic oxygen impacts bacterial ATP consumption and gene expression.

Cunningham-Bussel A, Zhang T, Nathan CF.

Proc Natl Acad Sci U S A. 2013 Nov 5;110(45):E4256-65. doi: 10.1073/pnas.1316894110. Epub 2013 Oct 21.

22.

Perspective: Graduation time.

Russell DG, Nathan CF.

Nature. 2013 Oct 10;502(7470):S7. doi: 10.1038/502S7a. No abstract available.

PMID:
24108080
23.

Nitrite impacts the survival of Mycobacterium tuberculosis in response to isoniazid and hydrogen peroxide.

Cunningham-Bussel A, Bange FC, Nathan CF.

Microbiologyopen. 2013 Dec;2(6):901-11. doi: 10.1002/mbo3.126. Epub 2013 Sep 8.

24.

Influence of allosteric regulators on individual steps in the reaction catalyzed by Mycobacterium tuberculosis 2-hydroxy-3-oxoadipate synthase.

Balakrishnan A, Jordan F, Nathan CF.

J Biol Chem. 2013 Jul 26;288(30):21688-702. doi: 10.1074/jbc.M113.465419. Epub 2013 Jun 11.

25.

Efficacy of nitazoxanide against clinical isolates of Mycobacterium tuberculosis.

Shigyo K, Ocheretina O, Merveille YM, Johnson WD, Pape JW, Nathan CF, Fitzgerald DW.

Antimicrob Agents Chemother. 2013 Jun;57(6):2834-7. doi: 10.1128/AAC.02542-12. Epub 2013 Mar 18.

26.

Nonsteroidal anti-inflammatory drug sensitizes Mycobacterium tuberculosis to endogenous and exogenous antimicrobials.

Gold B, Pingle M, Brickner SJ, Shah N, Roberts J, Rundell M, Bracken WC, Warrier T, Somersan S, Venugopal A, Darby C, Jiang X, Warren JD, Fernandez J, Ouerfelli O, Nuermberger EL, Cunningham-Bussel A, Rath P, Chidawanyika T, Deng H, Realubit R, Glickman JF, Nathan CF.

Proc Natl Acad Sci U S A. 2012 Oct 2;109(40):16004-11. doi: 10.1073/pnas.1214188109. Epub 2012 Sep 10.

27.

Mycobacterium tuberculosis gene Rv2136c is dispensable for acid resistance and virulence in mice.

Darby CM, Venugopal A, Ehrt S, Nathan CF.

Tuberculosis (Edinb). 2011 Sep;91(5):343-7. doi: 10.1016/j.tube.2011.06.007. Epub 2011 Jul 20.

28.

Genome-wide screen for Mycobacterium tuberculosis genes that regulate host immunity.

Beaulieu AM, Rath P, Imhof M, Siddall ME, Roberts J, Schnappinger D, Nathan CF.

PLoS One. 2010 Dec 10;5(12):e15120. doi: 10.1371/journal.pone.0015120.

29.

Killing of non-replicating Mycobacterium tuberculosis by 8-hydroxyquinoline.

Darby CM, Nathan CF.

J Antimicrob Chemother. 2010 Jul;65(7):1424-7. doi: 10.1093/jac/dkq145. Epub 2010 Apr 30.

PMID:
20435781
30.

Acid resistance in Mycobacterium tuberculosis.

Vandal OH, Nathan CF, Ehrt S.

J Bacteriol. 2009 Aug;191(15):4714-21. doi: 10.1128/JB.00305-09. Epub 2009 May 22. Review. No abstract available.

31.

Acid-susceptible mutants of Mycobacterium tuberculosis share hypersusceptibility to cell wall and oxidative stress and to the host environment.

Vandal OH, Roberts JA, Odaira T, Schnappinger D, Nathan CF, Ehrt S.

J Bacteriol. 2009 Jan;191(2):625-31. doi: 10.1128/JB.00932-08. Epub 2008 Nov 14.

32.

Pulmonary nodules in an infliximab-treated rheumatoid arthritis patient: a clinical pathology conference held by the Division of Rheumatology at Hospital for Special Surgery.

Bass AR, Schneider R, Sanders A, Flieder D, Nathan CF, Erkan D.

HSS J. 2007 Feb;3(1):119-25. doi: 10.1007/s11420-006-9032-1. No abstract available.

33.

A membrane protein preserves intrabacterial pH in intraphagosomal Mycobacterium tuberculosis.

Vandal OH, Pierini LM, Schnappinger D, Nathan CF, Ehrt S.

Nat Med. 2008 Aug;14(8):849-54. doi: 10.1038/nm.1795. Epub 2008 Jul 20.

34.

New approaches to filling the gap in tuberculosis drug discovery.

Casenghi M, Cole ST, Nathan CF.

PLoS Med. 2007 Nov 6;4(11):e293. No abstract available.

35.

Man is not a mouse: reply.

Fang FC, Nathan CF.

J Leukoc Biol. 2007 Mar;81(3):580. No abstract available.

PMID:
17332374
37.

Crystal structure and functional analysis of lipoamide dehydrogenase from Mycobacterium tuberculosis.

Rajashankar KR, Bryk R, Kniewel R, Buglino JA, Nathan CF, Lima CD.

J Biol Chem. 2005 Oct 7;280(40):33977-83. Epub 2005 Aug 10.

38.
39.

Characterization of a Mycobacterium tuberculosis proteasomal ATPase homologue.

Darwin KH, Lin G, Chen Z, Li H, Nathan CF.

Mol Microbiol. 2005 Jan;55(2):561-71.

40.

S-nitroso proteome of Mycobacterium tuberculosis: Enzymes of intermediary metabolism and antioxidant defense.

Rhee KY, Erdjument-Bromage H, Tempst P, Nathan CF.

Proc Natl Acad Sci U S A. 2005 Jan 11;102(2):467-72. Epub 2004 Dec 30.

41.

Identification of Mycobacterium tuberculosis counterimmune (cim) mutants in immunodeficient mice by differential screening.

Hisert KB, Kirksey MA, Gomez JE, Sousa AO, Cox JS, Jacobs WR Jr, Nathan CF, McKinney JD.

Infect Immun. 2004 Sep;72(9):5315-21. Erratum in: Infect Immun. 2009 Feb;77(2):927.

42.

The proteasome of Mycobacterium tuberculosis is required for resistance to nitric oxide.

Darwin KH, Ehrt S, Gutierrez-Ramos JC, Weich N, Nathan CF.

Science. 2003 Dec 12;302(5652):1963-6.

43.

Elevation of IL-18 in human sepsis.

Grobmyer SR, Lin E, Lowry SF, Rivadeneira DE, Potter S, Barie PS, Nathan CF.

J Clin Immunol. 2000 May;20(3):212-5.

PMID:
10941829
44.

Secretory leukocyte protease inhibitor, an inhibitor of neutrophil activation, is elevated in serum in human sepsis and experimental endotoxemia.

Grobmyer SR, Barie PS, Nathan CF, Fuortes M, Lin E, Lowry SF, Wright CD, Weyant MJ, Hydo L, Reeves F, Shiloh MU, Ding A.

Crit Care Med. 2000 May;28(5):1276-82.

PMID:
10834665
45.

Reactive nitrogen intermediates and the pathogenesis of Salmonella and mycobacteria.

Shiloh MU, Nathan CF.

Curr Opin Microbiol. 2000 Feb;3(1):35-42. Review.

PMID:
10679417
46.

Peptidomimetic fluoromethylketone rescues mice from lethal endotoxic shock.

Grobmyer SR, Armstrong RC, Nicholson SC, Gabay C, Arend WP, Potter SH, Melchior M, Fritz LC, Nathan CF.

Mol Med. 1999 Sep;5(9):585-94.

47.
48.

Heat shock protein 90 mediates macrophage activation by Taxol and bacterial lipopolysaccharide.

Byrd CA, Bornmann W, Erdjument-Bromage H, Tempst P, Pavletich N, Rosen N, Nathan CF, Ding A.

Proc Natl Acad Sci U S A. 1999 May 11;96(10):5645-50.

49.

Lethality of endotoxin in mice genetically deficient in the respiratory burst oxidase, inducible nitric oxide synthase, or both.

Nicholson SC, Grobmyer SR, Shiloh MU, Brause JE, Potter S, MacMicking JD, Dinauer MC, Nathan CF.

Shock. 1999 Apr;11(4):253-8.

PMID:
10220301
50.

Supplemental Content

Loading ...
Support Center